Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome With Constipation.

Journal Article (Journal Article;Systematic Review)

Irritable bowel syndrome (IBS) is a chronic functional bowel disorder affecting 1 in 10 people and associated with poor psychological health, reduced quality of life, and increased health care expenditure.1 The etiology is complex and incompletely understood.2 Approximately one-third of patients have IBS with constipation (IBS-C),1 for which there are licensed therapies available in the United States. We summarized comparative efficacy of these in a recent network meta-analysis of randomized controlled trials (RCTs).3 Tegaserod, a 5-hydroxytryptamine-4 receptor agonist, approved by the Food and Drug Administration (FDA) for IBS-C, was withdrawn in 2007 after a small excess number of cerebrovascular and cardiovascular ischemic events in patients taking the drug.4 However, since our network meta-analysis, it has been reintroduced in the United States. It is therefore important to understand its efficacy relative to other available licensed therapies for IBS-C.

Full Text

Duke Authors

Cited Authors

  • Black, CJ; Burr, NE; Ford, AC

Published Date

  • May 2020

Published In

Volume / Issue

  • 18 / 5

Start / End Page

  • 1238 - 1239.e1

PubMed ID

  • 31302307

Electronic International Standard Serial Number (EISSN)

  • 1542-7714

Digital Object Identifier (DOI)

  • 10.1016/j.cgh.2019.07.007


  • eng

Conference Location

  • United States